구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | therapeutic cytotoxic T lymphocytes (therapeutic cytotoxic T lymphocytes) Fred Hutchinson Cancer Center·Recurrent Melanoma 31 trials |
|---|---|
Overview Program | therapeutic cytotoxic T lymphocytes |
Overview Company | Fred Hutchinson Cancer Center |
Overview Modality | CGT |
Overview Target | Recurrent Melanoma |
Overview Indication | Recurrent Melanoma; Stage IV Melanoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Biomimetic M1 Macrophage Membrane-Camouflaged Nanoplatform Remodels Tumor Microenvironment for Enhanced Antitumor Immunity.. Immunotherapy has attracted increasing attention in cancer treatment, but its efficacy is greatly limited due to the low immunogenicity of tumors and immunosuppressive tumor microenvironment (TME). To address this, we constructed a biomimetic M1 macrophage membrane-Camouflag… |
Clinical Safety signal | Biomimetic M1 Macrophage Membrane-Camouflaged Nanoplatform Remodels Tumor Microenvironment for Enhanced Antitumor Immunity.. Immunotherapy has attracted increasing attention in cancer treatment, but its efficacy is greatly limited due to the low immunogenicity of tumors and immunosuppressive tumor microenvironment (TME). To address this, we constructed a biomimetic M1 macrophage membrane-Camouflag… |
Clinical Selected reported efficacy | ORR 4% |
Clinical Reported ORR | 4% |
Clinical Result source | ClinicalTrials.gov NCT03816332 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03816332 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | therapeutic cytotoxic T lymphocytes (therapeutic cytotoxic T lymphocytes) Fred Hutchinson Cancer Center·Recurrent Melanoma 31 trials |
|---|---|
Overview Program | therapeutic cytotoxic T lymphocytes |
Overview Company | Fred Hutchinson Cancer Center |
Overview Modality | CGT |
Overview Target | Recurrent Melanoma |
Overview Indication | Recurrent Melanoma; Stage IV Melanoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Biomimetic M1 Macrophage Membrane-Camouflaged Nanoplatform Remodels Tumor Microenvironment for Enhanced Antitumor Immunity.. Immunotherapy has attracted increasing attention in cancer treatment, but its efficacy is greatly limited due to the low immunogenicity of tumors and immunosuppressive tumor microenvironment (TME). To address this, we constructed a biomimetic M1 macrophage membrane-Camouflag… |
Clinical Safety signal | Biomimetic M1 Macrophage Membrane-Camouflaged Nanoplatform Remodels Tumor Microenvironment for Enhanced Antitumor Immunity.. Immunotherapy has attracted increasing attention in cancer treatment, but its efficacy is greatly limited due to the low immunogenicity of tumors and immunosuppressive tumor microenvironment (TME). To address this, we constructed a biomimetic M1 macrophage membrane-Camouflag… |
Clinical Selected reported efficacy | ORR 4% |
Clinical Reported ORR | 4% |
Clinical Result source | ClinicalTrials.gov NCT03816332 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03816332 |
추천 비교
추천 비교